|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
08189 TEDA BIOMEDICAL
Nominal 
0.445 +0.005 (+1.136%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 385,482 | -3.145% | 397,998 | 449,676 | 476,385 | 369,355 |
| Cost of Sales | (365,259) | -3.020% | (376,632) | (433,281) | (430,780) | (328,963) |
| Gross Profit | 20,223 | -5.349% | 21,366 | 16,395 | 45,605 | 40,392 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | (2,409) | -- | -- | -- | (3,158) | -- | |
| Change in FV & Impairment on Others | (1,109) | -35.053% | (1,707) | (315) | (22,945) | (14,380) | |
| Profit / (Loss) on Disposal | -- | -- | -- | 5,912 | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | 297 | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 1,001 | (1,938) | |
| Profit / (Loss) before Taxation | (38,207) | 218.059% | (12,012) | (26,495) | (44,839) | (50,001) | |
| Taxation | 221 | -78.799% | 1,044 | (151) | 55 | (363) | |
| Profit / (Loss) from Discontinued Operations | 1,846 | -- | (5,602) | -- | -- | -- | |
| Non-controlling Interests | 8,337 | -- | (3,589) | (1,460) | 2,529 | 2,365 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (27,802) | 37.910% | (20,160) | (28,106) | (42,255) | (47,998) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 4,533 | -7.920% | 4,923 | 5,639 | 5,036 | 805 |
| Depreciation & Amortisation | 9,128 | -16.603% | 10,945 | 15,390 | 9,513 | 7,104 |
| Directors' Emoluments | -- | -- | 1,120 | 1,387 | 1,591 | 1,711 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified (Modified Report) | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -1.460 | 37.736% | -1.060 | -1.480 | -2.230 | -2.530 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.007) | (0.007) | (0.004) | 0.019 |
| NBV per share ($) | 0.012 | -- | 0.026 | 0.037 | 0.053 | 0.076 |
| Remarks: | Real time quote last updated: 17/04/2025 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -27,802,241 |
| %Change | 37.910% |
| EPS / (LPS) | RMB -0.015 |
| NBV Per Share (¥) | RMB 0.012 |